User profiles for M. De Tursi
MICHELE DE TURSIProfessore Aggregato, Università G. D'Annunzio Verified email at unich.it Cited by 3982 |
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
…, E Porreca, M Candeloro, M De Tursi… - Cochrane Database …, 2016 - cochranelibrary.com
Background Venous thromboembolism (VTE) often complicates the clinical course of cancer.
The risk is further increased by chemotherapy, but the trade‐off between safety and efficacy …
The risk is further increased by chemotherapy, but the trade‐off between safety and efficacy …
[HTML][HTML] Effect of gender on the outcome of patients receiving immune checkpoint inhibitors for advanced cancer: a systematic review and meta-analysis of phase III …
…, G Cognetti, M De Tursi, C Natoli, M Barba… - Journal of Clinical …, 2018 - mdpi.com
Evidence has recently emerged on the influence of gender on the immune system. In this
systematic review and meta-analysis of phase III randomized clinical trials (RCTs), we explored …
systematic review and meta-analysis of phase III randomized clinical trials (RCTs), we explored …
[HTML][HTML] A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
…, M Michiara, P Di Marino, N Tinari, M De Tursi… - … for immunotherapy of …, 2019 - Springer
Background Recent evidence suggested a potential correlation between overweight and the
efficacy of immune checkpoint inhibitors (ICIs) in cancer patients. Patients and methods We …
efficacy of immune checkpoint inhibitors (ICIs) in cancer patients. Patients and methods We …
[HTML][HTML] Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
…, C Bareggi, O Nigro, A Tuzi, M De Tursi… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
… 2 ; overweight, 25 kg/m 2 ≤ BMI ≤29.9 kg/m 2 ; obese, BMI ≥30 kg/m 2 . In order to
properly weighing the role of baseline concomitant medication, their association with ECOG-PS, …
properly weighing the role of baseline concomitant medication, their association with ECOG-PS, …
[HTML][HTML] Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study
…, O Arrieta, A Stépanian, K Smit, M De Tursi… - …, 2017 - ncbi.nlm.nih.gov
In ambulatory patients with solid cancer, routine thromboprophylaxis to prevent venous
thromboembolism is not recommended. Several risk prediction scores to identify cancer patients …
thromboembolism is not recommended. Several risk prediction scores to identify cancer patients …
[HTML][HTML] Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients
…, A Chella, F Malorgio, F Guglielmi, M De Tursi… - Journal of Thoracic …, 2015 - Elsevier
Introduction The potential to accurately quantify epidermal growth factor receptor (EGFR)
mutations in plasma from non–small-cell lung cancer patients would enable more rapid and …
mutations in plasma from non–small-cell lung cancer patients would enable more rapid and …
[HTML][HTML] Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
…, C Morelli, M Libertini, A Parisi, M De Tursi… - Nature Medicine, 2023 - nature.com
Genomics has greatly improved how patients with cancer are being treated; however,
clinical-grade genomic biomarkers for chemotherapies are currently lacking. Using whole-genome …
clinical-grade genomic biomarkers for chemotherapies are currently lacking. Using whole-genome …
Clinical outcomes of patients with advanced cancer and pre‐existing autoimmune diseases treated with anti‐programmed death‐1 immunotherapy: a real‐world …
…, A Grassadonia, D Brocco, N Tinari, M De Tursi… - The …, 2019 - academic.oup.com
Background Patients with a history of autoimmune diseases (AIDs) have not usually been
included in clinical trials with immune checkpoint inhibitors. Materials and Methods …
included in clinical trials with immune checkpoint inhibitors. Materials and Methods …
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant …
The immune system seems to play a fundamental role in breast cancer responsiveness to
chemotherapy. We investigated two peripheral indicators of immunity/inflammation, ie …
chemotherapy. We investigated two peripheral indicators of immunity/inflammation, ie …
Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients
…, A Grassadonia, P Di Marino, N Tinari, M De Tursi… - Clinical lung cancer, 2019 - Elsevier
Background Immune-related adverse events (irAEs) developed during immunotherapy with
anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in patients with …
anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in patients with …